Patents Examined by Joseph Kosack
  • Modulators of sphingosine phosphate receptors
    Patent number: 8796318
    Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: August 5, 2014
    Assignee: The Scripps Research Institute
    Inventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
  • 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 8796319
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: August 5, 2014
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • Heteroaryls and uses thereof
    Patent number: 8796314
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, CY, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: August 5, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Zhan Shi, Irache Visiers, Tricia J. Vos, Stepan Vyskocil
  • Compounds, compositions and methods comprising oxadiazole derivatives
    Patent number: 8796321
    Abstract: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: August 5, 2014
    Assignee: PATH Drug Solutions
    Inventors: Graham Peter Jones, Kevin James Doyle
  • Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
    Patent number: 8785489
    Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: July 22, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Bennett Farmer, Neil Alexander Farrow, Donghong Amy Gao, Alexander Heim-Riether, Lana Louise Smith Keenan, Ingo Andreas Mugge, Steven John Taylor, Zhaoming Xiong, Yang Yu, Qiang Zhang
  • Surface active blocked isocyanates and coating compositions thereof
    Patent number: 8784555
    Abstract: Disclosed herein is a surface active adhesion promoting agent and a coating composition comprising the surface active adhesion promoting agent. The adhesion promoting agent is a blocked isocyanate functional siloxane containing material. Addition of small amount of the adhesion promoting agent to a coating composition, especially clearcoat compositions, helps to provide adhesion to a variety of materials that may be subsequently applied to the coating composition.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: July 22, 2014
    Assignee: Axalta Coating Systems IP Co., LLC
    Inventor: Jun Lin
  • Detection of hydrogen peroxide
    Patent number: 8785652
    Abstract: The present invention provides compounds useful for detection of hydrogen peroxide and methods of using same.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: July 22, 2014
    Assignee: Promega Corporation
    Inventors: Dieter Klaubert, John Shultz, James Unch, Michael P. Valley, Hui Wang, Wenhui Zhou
  • Pyridinonyl PDK1 inhibitors
    Patent number: 8778977
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: July 15, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • Salts of desvenlafaxine and a method of their preparation
    Patent number: 8779005
    Abstract: The invention deals with new salts of the desvenlafaxine base of formula (I) with oxalic acid, the new salts being the hydrogen oxalate of formula (II) in the proportion of desvenlafaxine:oxalic acid of 1:1 and hemioxalate of formula (III) in the proportion of desvenlafaxine:oxalic acid of 2:1.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: July 15, 2014
    Assignee: Zentiva k.s.
    Inventors: Ludek Ridvan, Petr Hruby, Stanislav Radl, Hana Brusova, Lukas Krejcik, Tomas Pekarek, Natalia Csokova, Anna Zerzanova
  • Methods for preparing ruthenium carbene complex precursors and ruthenium carbene complexes
    Patent number: 8779152
    Abstract: A method for preparing a ruthenium carbene complex precursor includes reacting a ruthenium refinery salt with a hydrogen halide to form a ruthenium intermediate, and reacting the ruthenium intermediate with an L-type ligand to form the ruthenium carbene complex precursor. A method for preparing a ruthenium vinylcarbene complex includes converting a ruthenium carbene complex precursor into a ruthenium hydrido halide complex, and reacting the ruthenium hydrido halide complex with a propargyl halide to form the ruthenium vinylcarbene complex. A method for preparing a ruthenium carbene complex includes converting a ruthenium carbene complex precursor into a ruthenium carbene complex having a structure (PR1R2R3)2Cl2Ru?CH—R4, wherein R1, R2, R3, and R4 are alike or different, and wherein covalent bonds may optionally exist between two or more of R1, R2, and R3.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: July 15, 2014
    Assignee: Elevance Renewable Sciences, Inc.
    Inventors: Linda A. Kunz, Steven A. Cohen, Melvin L. Luetkens, Jr.
  • Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
    Patent number: 8779128
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 15, 2014
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Iridium-based complexes for ECL
    Patent number: 8772486
    Abstract: Novel iridium-based Ir (III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: July 8, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
  • Compounds as opioid receptor modulators
    Patent number: 8772325
    Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: July 8, 2014
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
  • Peptide derivatives with therapeutic activity
    Patent number: 8765798
    Abstract: Dipeptide compounds containing a histidine residue proved to have interesting blocking activity on secondary products from lipid oxidative stress, in particular on unsaturated aldehydes such as malondialdehyde and hydroxynonenal, which are known to contribute to the inset of quite a number of chronic pathologies such as neurodegenerative, inflammatory chronic, cardiovascular diseases, diabetes complications and cataract.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: July 1, 2014
    Assignee: Flamma S.p.A.
    Inventors: Gianpaolo Negrisoli, Renato Canevotti
  • Therapeutic compounds
    Patent number: 8765812
    Abstract: Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: July 1, 2014
    Assignee: Fibrotech Therapeutics Pty Ltd
    Inventors: Spencer John Willams, David Stapleton, Steven Zammit, Darren James Kelly, Richard Ernest Gilbert, Henry Krum
  • Methods and systems for making thiol compounds from terminal olefinic compounds
    Patent number: 8765984
    Abstract: The application discloses thiol ester molecules and ?-hydroxy thiol ester molecules having a thiol group located on one of the final two carbon atoms in a carbon chain or a terminal or ?-hydroxyl groups, respectively. The disclosed thiol ester molecules and or ?-hydroxyl thiol ester molecules es may be made from unsaturated ester molecules having one or more terminal alkene groups. The disclosed techniques also provide methods for making unsaturated ester molecules having one or more terminal alkene groups by the metathesis of unsaturated esters having one or more internal carbon-carbon double bonds (e.g. natural source oils). The thiol ester molecules or ?-hydroxy thiol ester molecule may be used in reactions with isocyanate monomers, epoxide monomer, or material having multiple alkene groups to make sealants, coatings, adhesives, and other products.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: July 1, 2014
    Assignee: Chevron Phillips Chemical Company LP
    Inventor: Thomas A. Upshaw
  • Certain heterocycles, compositions thereof, and methods for their use
    Patent number: 8759380
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: June 24, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Chihyuan Chuang, Scott Collibee, Pu-Ping Lu, Bradley Morgan, Alex Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang
  • Organic compounds
    Patent number: 8759365
    Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: June 24, 2014
    Assignee: Novartis AG
    Inventors: Muneto Mogi, Toshio Kawanami, Ken Yamada, Kayo Yasoshima, Hidetomo Imase, Takahiro Miyake, Osamu Ohmori
  • Inhibitors of cytochrome P450
    Patent number: 8759379
    Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: June 24, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Manoj C. Desai, Hon C. Hui, Hongtao Liu, Lianhong Xu
  • Panchromatic photosensitizers and dye-sensitized solar cell using the same
    Patent number: 8759521
    Abstract: Panchromatic photosensitizers having a Formula of ML1L2X were synthesized, wherein M represents ruthenium atom; X represents a monodentate anion; L1 is heterocyclic bidentate ligand having one of formulae listed below: wherein G2 has one of formulae listed below: and L2 is a tridentate ligand having a formula listed below: Substituents R1, R2, R3 and R4 of L1 are the same or different and are selected from the group consisting of hydrogen, halogen, amino-group alkyl, alkoxy, alkylthio, alkylamino, halogenated alkyl, phenyl and substituted phenyl group. Substituents R5, R6 and R7 of L2 are the same or different and are selected from the group consisting of carboxylic, carboxylate, sulfonic acid, sulfonate, phosphoric acid and phosphate. The above-mentioned photosensitizers are suitable to use as sensitizers for fabrication of high efficiency dye-sensitized solar cell.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: June 24, 2014
    Assignee: National Tsing Hua University
    Inventors: Yun Chi, Kellen Chen, Yi-Huan Hong, Pi-Tai Chou, Bo-So Chen